Organized by:
ISD_Mainidentifier_RGB_transparent.fw.pn
MOTAC_Logo_Jata - EN.PNG
MSIDC logo transparent.fw.png
Supported by:
myceb_logo_180mm_FC_RGB.jpg
ISID Logo

9 Babcock Street, Unit 3

Brookline, MA 02446

United States

info@isid.org

Tel: +1 (617) 277-0551

Fax: +1 (617) 278-9113

  • White Facebook Icon
  • White Twitter Icon

© 2019 International Society for Infectious Diseases

ABSTRACTS

Abstract Submission for the 19th ICID has been closed.

Abstract acceptance notifications will be sent by the end of November.

GENERAL INFORMATION

  • All abstracts for the 19th ICID must be submitted electronically through the electronic abstract submission system

  • All abstracts must be submitted in English

  • All abstracts must be received on or before October 25, 2019 (extended to November 1, 2019 - midnight, EST)

  • All abstracts have a 350 word limit of text (not including presenter information and title)

  • Abstract acceptance notifications will be sent by November 30, 2019

  • Based on previous ICID's, more than 800 abstracts will be presented during the congress. Eighty reviewers from more than 30 countries are reviewing and scoring abstracts.

  • Abstracts are reviewed and scored taking into consideration the quality and originality of the work, the scientific content, and presentation

  • Only highest scored accepted abstracts will be published as an online supplement to the International Journal for Infectious Diseases (IJID)

 

ABSTRACT TOPICS

The ICID Program Committees invite submission of abstracts of excellent quality in all areas related to infectious diseases.

Animal models, pathogenesis and host defenses

Antimicrobials: mechanisms and spectrum

Diagnostics and molecular technologies

Emerging and re-emerging infectious diseases

Infection prevention and control

Mycology, fungal infections and antifungal drugs

Vector control

Other

Antimicrobial resistance

Antimicrobials: pharmacology, PK/PD

Digital health and innovation

Epidemic preparedness

Healthcare associated infections and critical care

Parasitology and parasitic infections

Travel medicine and travel health

Virology and viral infections (non-HIV)

Antimicrobials: antimicrobial stewardship

Bacterial Infections

Displaced populations, refugees, and migrants

HIV/AIDS and other retroviruses

One Health

Pediatric and perinatal infections

Tuberculosis and other mycobacterial infections

Zoonoses and infections in animals

Antimicrobials: clinical trials

Clinical case report/series

Economics, health policy, and implementation

Immunocompromised host (non-HIV)

Infectious disease surveillance and notification

Sexually transmitted infections

Vaccines and vaccine development

 

ABSTRACT CATEGORIES

Abstracts may be accepted into one of three categories:

Oral Presentation

Highest scoring abstracts will be selected for oral presentations. The presenting author will be required to make a 7-minute PowerPoint presentation that concisely summarizes the research question, methods used, the results and their significance. Abstracts accepted for oral presentation will be published as an online supplement to the International Journal of Infectious Diseases.

Poster Presentation

The presenting author will be obliged to present the poster during the moderated poster session to which it has been assigned. Highest scoring abstracts accepted for poster presentation will be published as an online supplement to the International Journal of Infectious Diseases (IJID).

ePoster Presentation

Abstracts accepted into this category will be available for viewing and discussion on computer terminals at the ICID. Highest scoring abstracts accepted for electronic poster presentation will be published as an online supplement to the International Journal of Infectious Diseases (IJID).

Presenters who do not attend the session for which they have been scheduled will be ineligible to submit an abstract for the next ICID. Those abstracts will not be published in the International Journal for Infectious Diseases.

  • Abstracts must be based on original results that have not or will not be published or presented before the 19th ICID begins on February 20, 2020.

  • All abstracts have a 350 word limit of text (not including presenter information and title).

RESEARCH ABSTRACTS

It is recommended that research abstracts follow the format below:

  • Background: A statement of the hypothesis or research question.

  • Methods & Materials: An explanation of the study design and experimental method and materials used.

  • Results: A concise summary of the major findings of the experiment or study. Sufficient data must be provided to permit evaluation by the reviewers and public reading of the abstract. Statements such as "additional information to be presented at the meeting" are not acceptable.

  • Conclusion: Summary of the overall findings and the importance of the study.

DO NOT repeat these section headers in your abstract body! Do not format the complete abstract in bold or italic letters!

Abstracts that represent the presentation of investigations of compounds that involve inadequate numbers of study subjects, or in vitro studies of non-representative microbiologic strains, or abstracts that lack quantitative or qualitative data will not be accepted. Authors are discouraged from submitting multiple abstracts from the same project. Each abstract will be judged on its own merits without reference to other submissions. Repetitive abstracts will be rejected.

CLINICAL CASE REPORTS

A Case Report is a brief description of a particular condition that is unusual and also provides new insights into diagnosis or clinical management. A case report must make a distinct, novel contribution to the understanding of the etiologic agent, its clinical manifestations, and/or its diagnosis or treatment. 

 

It is recommended that clinical case reports follow the format below:

  • Background: A statement on the particular condition that is unusual.

  • Case Description: A description of key features of the case. Sufficient data must be provided to permit evaluation by the reviewers and public reading of the abstract.

  • Discussion: A concise discussion of the distinct, novel contribution of the case to the understanding of the disease, its clinical manifestations, and/or its diagnosis or treatment. 

  • Conclusion: Summary of the overall findings and the importance of the case report. 

 

DO NOT repeat these section headers in your abstract body! Do not format the complete abstract in bold or italic letters!

Case reports must be authentic, understandable, educational and clinically interesting to an international audience of healthcare professionals, researchers and others in all infectious diseases subspecialties. Each case report will be judged on its own merits without reference to other submissions. Repetitive case reports will be rejected.

  • Submitting authors are required to ensure that all listed co-authors have reviewed the abstract, take responsibility for its content and agree with being listed as co-author.

  • All potential conflicts of interest for each co-author must be provided. Potential conflicts of interest include, but are not limited to, commercial interest in the research, and financial or in-kind support for the research, and financial or in-kind support for the research from entities with commercial interest in the research.

  • Each abstract will be reviewed and scored by two reviewers for the quality and originality of the research, the scientific content and presentation. A notice of acceptance or rejection will be sent to the submitting authors only. It is the responsibility of the submitting author to notify other co-authors of the Committee's decision. Session assignments will be mailed by December 15, 2019 to the address given for correspondence.

  • The abstract review process is blinded, meaning that the authors' names and affiliations are not disclosed to the reviewers.

  • Authors are encouraged to submit their abstracts as early as possible.

  • Acceptance of the abstract in the program and assignment to a session are determined solely by the Program Committee based on the abstract's subject matter and combined reviewer scores and comments. Decisions of the Program Committee are final. Because of the logistics of assigning abstracts to sessions and the number of abstracts received, requests for particular types of presentations, sessions, days, or times will not be considered by the Program Committee.

  • Presenters of accepted abstracts must be registered and attend the 19th ICID in order to have the abstract published in the online supplement to the International Journal of Infectious Diseases (IJID).

  • Highest scoring abstracts will be published in the supplement to the IJID as is.

  • By submitting an abstract the author(s) agree to transfer all copyrights to ISID and to allow publication of submitted information on the ISID web site, the International Journal of Infectious Diseases (IJID) or other Society related publications.

  • Instructions will be sent to the authors whose abstracts are accepted for oral or poster presentation. For each abstract accepted for presentation, at least one author must attend the Congress and present the contribution.

  • If the registration fee of the presenting author is not received by January 31, 2020 the abstract will not be published in the Final Program.

 

Should you require further explanation, send an e-mail to info@isid.org or call ISID at +1 (617) 277–0551.

 

SUBMISSION GUIDELINES